Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Purple Biotech ( (PPBT) ) has provided an announcement.
On April 27, 2026, Purple Biotech reported new preclinical data for IM1240, the lead tri-specific antibody from its CAPTN-3 platform, showing potent anti-tumor activity in all seven tested treatment-resistant patient-derived tumor samples, including PD-1- and chemo-resistant head and neck cancers and bladder cancer. The data, generated at Mount Sinai’s Tisch Cancer Institute, highlighted the critical role of IM1240’s NKG2A arm in enhancing anti-tumor efficacy and therapeutic index, and showed induction of mature tertiary lymphoid structures and favorable immune cell shifts in a non-small cell lung cancer biopsy, reinforcing the program’s potential to address resistant tumors across multiple indications and underpinning a sizable future market opportunity if clinical results align with these findings.
The CAPTN-3 platform uses proprietary capping technology to confine CD3-driven immune activation to the tumor microenvironment, aiming to expand the therapeutic window relative to conventional T-cell engagers. With IM1240 and IM1305 still in preclinical development and additional clinical-stage assets awaiting further funding or partnerships, the new IM1240 dataset strengthens Purple Biotech’s scientific case and could improve its positioning for future clinical development, collaborations, or investment within the competitive oncology immunotherapy landscape.
The most recent analyst rating on (PPBT) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.
Spark’s Take on PPBT Stock
According to Spark, TipRanks’ AI Analyst, PPBT is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue, widening losses, and continued cash burn alongside a shrinking equity base). Technicals are also bearish with negative momentum and price below key moving averages, only partially offset by oversold signals. Valuation contributes little support due to unprofitability and no dividend data.
To see Spark’s full report on PPBT stock, click here.
More about Purple Biotech
Purple Biotech Ltd. is a clinical-stage biotechnology company developing next-generation cancer immunotherapies, with a focus on its CAPTN-3 platform of masked tri-specific antibodies that target tumors while engaging both T cells and NK cells. The company’s lead candidate, IM1240, is advancing toward clinical trials, while a second CAPTN-3 candidate, IM1305, and legacy assets CM24 and NT219 remain in preclinical or partnering-dependent development.
Average Trading Volume: 14,384
Technical Sentiment Signal: Strong Sell
Current Market Cap: $6.22M
For detailed information about PPBT stock, go to TipRanks’ Stock Analysis page.